SCHEMBL14750672

SCHEMBL14750672

COc1ccc(C)c(OC2(C(=O)O)CC2)c1OC

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ALDH1A1 P00352 3/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ GAA P10253 1/20 0.40
▸ KDM4E B2RXH2 4/20 0.38
▸ LMNA P02545 1/20 0.38
▸ ACHE P22303 1/20 0.37
▸ ABCG2 Q9UNQ0 1/20 0.36
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ CHRNA7 P36544 1/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ HPGD P15428 1/20 0.35
▸ LY96 Q9Y6Y9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14750671 0.87 ALDH1A1 (0.40) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14734712 0.74 KDM4E (0.44) MAPTALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL20790112 0.74 LMNA (0.39) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14749775 0.73 DGAT1 (0.40) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14734716 0.73 TUBB4A (0.45) ALDH1A1KDM4EHPGD
SCHEMBL1226775 0.72 ALDH1A1 (0.46) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL29767819 0.72 ALDH1A1 (0.46) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14750683 0.72 TSHR (0.41) TDP1MAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL14734772 0.71 KDR (0.41) SMN1; SMN2NPC1RAB9A
SCHEMBL24234121 0.70 TSHR (0.47) TDP1MAPTALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 — — US disclosed
US-9051290-B2 Biaryl phosphodiesterase inhibitors LEO PHARMA A/S (DK) 2015-06-09 — — US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059853-A1 BIARYL PHOSPHODIESTERASE INHIBITORS PDE3B, PDE3A, PDE4A TDP1 49/4885MAPT 4737/4885ALDH1A1 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback